In partnership with
Letter from The Editor
Interview with the IASCL President
Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer
Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer
Benefits of chest CT screening
New standard of care in extensive-stage small-cell lung cancer
No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype
Next generation immunotherapy in non-small-cell lung cancer
Combination therapies: Where are we in 2018?
Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer
PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib
Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC
Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative
Unmet needs in surgical management of malignant pleural mesothelioma
Angiogenic and stromal biomarkers in malignant mesothelioma
Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer
Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer
Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer
Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement
Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cancer
Entrectinib treatment in patients with ROS1+ NSCLC
Small-cell lung cancer circulating tumour cell derived explants
Spread through air spaces is prognostic in lung neuroendocrine tumours
Prognostic value of distant organ-specific metastases in newly diagnosed lung neuroendocrine tumours
Top image: © iStockphoto
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP